DEMİR, M. Et Al. 2018. Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.. APASL Single Topic Conference , (İstanbul, Turkey).

DEMİR, M., DANIŞ, N., KANİ, H. T., YILDIRIM, A. E., BALKAN, A., DEĞERTEKİN, M. B., ... YAPALI, S.(2018). Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience. . APASL Single Topic Conference, İstanbul, Turkey

DEMİR, MEHMET Et Al. "Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.," APASL Single Topic Conference, İstanbul, Turkey, 2018

DEMİR, MEHMET Et Al. "Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.." APASL Single Topic Conference , İstanbul, Turkey, 2018

DEMİR, M. Et Al. (2018) . "Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.." APASL Single Topic Conference , İstanbul, Turkey.

@conferencepaper{conferencepaper, author={MEHMET DEMİR Et Al. }, title={Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.}, congress name={APASL Single Topic Conference}, city={İstanbul}, country={Turkey}, year={2018}}